The Noncoding Mutational Landscape of Pancreatic Cancer Reveals Recurrent Somatic Mutations in Enhancer Regions

While the coding genome of pancreatic cancer has been characterized in detail, features of the noncoding genome remain relatively unexplored. We used whole-genome sequencing to study the coding and noncoding genomes (promoters, enhancers, and noncoding-nonenhancer regions) in two unique patient coho...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer research communications Jg. 5; H. 10; S. 1839 - 1851
Hauptverfasser: Hayashi, Akimasa, Ho, Yu-Jui, Makohon-Moore, Alvin P., Zucker, Amanda, Hong, Jungeui, Umeda, Shigeaki, Karnoub, Elias-Ramzey, Huang, Jinlong, Baez, Priscilla, Kappagantula, Rajya, Melchor, Jerry P., Park, Wungki, O’Reilly, Eileen M., Socci, Nicholas D., Oki, Shinya, Iacobuzio-Donahue, Christine A.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 01.10.2025
Schlagworte:
Animals
Enhancer Elements, Genetic
Gene Expression Regulation, Neoplastic
Humans
Mice
Mutation
Pancreatic Neoplasms - genetics
Pancreatic Neoplasms - pathology
Promoter Regions, Genetic
Whole Genome Sequencing
ISSN:2767-9764, 2767-9764
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:While the coding genome of pancreatic cancer has been characterized in detail, features of the noncoding genome remain relatively unexplored. We used whole-genome sequencing to study the coding and noncoding genomes (promoters, enhancers, and noncoding-nonenhancer regions) in two unique patient cohorts. We find that treated cancers have a significantly higher mutational burden than untreated cancers in all four genomic regions. However, the relative proportion of mutations in each region is preserved despite treatment-induced genetic bottlenecks. Compared with other noncoding regions, enhancers have a lower number of mutations/Mb. Enhancers also have a distinct mutational signature with enrichment of SBS39. Enhancer sequences were segregated into conserved and nonconserved regions based on the overlap of predicted orthologous regions in the human and mouse genomes and the conserved regions screened for recurrent somatic mutations. We find that recurrent somatic mutations in conserved enhancer regions largely correspond to those associated with known transcription factors with a role in pancreatic development and cancer, including KLF5 and TP63. Transcriptional expression based on RNA sequencing data of cancers with enhancer mutations showed significantly different levels of expression, most often a loss of expression, compared with cancers without enhancer mutations, suggesting a functional effect. These findings expand our knowledge of the noncoding genome in pancreatic cancer and point to an unexplored role of conserved enhancer mutations for pancreatic cancer as well. Recurrent somatic mutations in enhancer regions that control pancreatic lineage genes represent a previously unrecognized source of genetic alteration in pancreatic cancer.
ISSN:2767-9764
2767-9764
DOI:10.1158/2767-9764.CRC-24-0167